Share Price and Basic Stock Data
Last Updated: December 17, 2025, 3:30 am
| PEG Ratio | 3.15 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Procter & Gamble Health Ltd, a prominent player in the pharmaceuticals sector, reported a current market price of ₹5,620 and a market capitalization of ₹9,330 Cr. The company has demonstrated a consistent revenue trajectory, with total sales for the trailing twelve months (TTM) standing at ₹1,273 Cr. This reflects a notable growth from ₹1,114 Cr in June 2022. The quarterly sales figures reveal fluctuations, with the latest reported quarter in March 2025 recording ₹311 Cr, following a high of ₹339 Cr in June 2025. The revenue growth story, while commendable, shows some volatility, particularly in the most recent quarters, where sales dipped to ₹252 Cr in March 2024 before rebounding. This pattern suggests that while the company is efficient in generating revenue, it faces challenges in maintaining consistent quarterly growth, which could be a point of concern for potential investors.
Profitability and Efficiency Metrics
Profitability metrics for Procter & Gamble Health Ltd appear robust, with a reported net profit of ₹301 Cr and an impressive return on equity (ROE) of 36.4%. The operating profit margin (OPM) stood at 27%, indicating the company’s ability to manage its costs effectively while generating substantial profits from its operations. However, the quarterly operating profit has shown some inconsistency, dipping to ₹45 Cr in June 2023 from ₹109 Cr in December 2022. This volatility in operating profit raises questions about the sustainability of margins in the face of fluctuating sales. The interest coverage ratio (ICR) is extraordinarily high at 764.51x, suggesting that the company is in an excellent position to cover its interest obligations, with negligible borrowings of just ₹6 Cr. This financial cushion adds to the overall picture of a company that is not only profitable but also well-positioned to handle its financial commitments.
Balance Sheet Strength and Financial Ratios
The balance sheet of Procter & Gamble Health Ltd reflects a solid financial foundation, with total reserves amounting to ₹603 Cr and minimal borrowings. The company’s current ratio of 2.44x indicates a comfortable liquidity position, suggesting it can easily meet its short-term liabilities. The price-to-book value (P/BV) ratio is reported at 15.90x, which may seem elevated compared to industry norms, indicating that the stock is priced at a premium. However, this could also reflect investor confidence in the company’s strong fundamentals. Furthermore, the return on capital employed (ROCE) stands at an impressive 47.8%, reinforcing the efficiency with which the company utilizes its capital to generate profits. Despite these strengths, the high P/BV ratio could deter value-oriented investors looking for bargains, and the ongoing fluctuations in profitability metrics may raise concerns about future performance.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Procter & Gamble Health Ltd indicates a stable and confident investor base. Promoters hold 51.82% of the shares, which suggests a strong commitment to the company’s long-term vision. Institutional investors, including foreign institutional investors (FIIs) at 7.24% and domestic institutional investors (DIIs) at 13.90%, demonstrate a moderate level of institutional interest. The public shareholding stands at 27.05%, which, while substantial, has been gradually decreasing. This diminishing public stake may indicate a consolidation of ownership, potentially leading to less liquidity in the stock. The number of shareholders has also declined to 50,006, reflecting a trend that could concern retail investors. Overall, while the promoter stake provides security, the declining public and institutional participation might raise questions about broader market sentiment towards the stock.
Outlook, Risks, and Final Insight
Looking ahead, Procter & Gamble Health Ltd faces a mixed outlook. On the one hand, the company enjoys strong profitability metrics and a solid balance sheet, which are significant strengths. However, the volatility in revenue and operating profit, along with the high valuation multiples, could pose risks. Investors should be wary of the potential for fluctuations in sales, especially given the recent quarterly dips. Additionally, the declining public shareholding and investor interest could signal caution. While the company is well-positioned financially, the sustainability of its growth and profitability remains to be seen. For retail investors, this stock may represent a well-managed entity but comes with the caveat of needing to monitor its performance closely to navigate the inherent risks associated with its fluctuating revenue trends.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 143 Cr. | 114 | 235/84.3 | 31.7 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,260 Cr. | 391 | 479/192 | 88.2 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.0 Cr. | 43.1 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 46.1 Cr. | 31.5 | 32.0/17.0 | 110 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,307.87 Cr | 1,151.54 | 51.89 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 296 | 298 | 310 | 321 | 301 | 305 | 310 | 252 | 284 | 313 | 310 | 311 | 339 |
| Expenses | 237 | 207 | 201 | 241 | 256 | 216 | 208 | 185 | 236 | 199 | 186 | 230 | 248 |
| Operating Profit | 59 | 91 | 109 | 80 | 45 | 89 | 102 | 67 | 48 | 114 | 123 | 81 | 90 |
| OPM % | 20% | 31% | 35% | 25% | 15% | 29% | 33% | 27% | 17% | 36% | 40% | 26% | 27% |
| Other Income | 3 | 3 | 5 | 5 | 5 | 6 | 5 | 2 | -18 | 3 | 4 | 3 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 7 | 7 | 8 | 6 | 6 | 6 | 7 | 7 | 7 | 6 | 6 | 5 | 5 |
| Profit before tax | 55 | 87 | 105 | 79 | 44 | 88 | 100 | 63 | 23 | 111 | 122 | 79 | 89 |
| Tax % | 25% | 26% | 27% | 25% | 32% | 26% | 28% | 26% | 26% | 26% | 25% | 22% | 25% |
| Net Profit | 41 | 64 | 77 | 59 | 30 | 66 | 72 | 47 | 17 | 82 | 91 | 61 | 66 |
| EPS in Rs | 24.81 | 38.35 | 46.27 | 35.66 | 17.96 | 39.50 | 43.42 | 28.05 | 10.11 | 49.60 | 54.76 | 36.86 | 39.87 |
Last Updated: August 20, 2025, 5:00 am
Below is a detailed analysis of the quarterly data for Procter & Gamble Health Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 339.00 Cr.. The value appears strong and on an upward trend. It has increased from 311.00 Cr. (Mar 2025) to 339.00 Cr., marking an increase of 28.00 Cr..
- For Expenses, as of Jun 2025, the value is 248.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 230.00 Cr. (Mar 2025) to 248.00 Cr., marking an increase of 18.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 90.00 Cr.. The value appears strong and on an upward trend. It has increased from 81.00 Cr. (Mar 2025) to 90.00 Cr., marking an increase of 9.00 Cr..
- For OPM %, as of Jun 2025, the value is 27.00%. The value appears strong and on an upward trend. It has increased from 26.00% (Mar 2025) to 27.00%, marking an increase of 1.00%.
- For Other Income, as of Jun 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 89.00 Cr.. The value appears strong and on an upward trend. It has increased from 79.00 Cr. (Mar 2025) to 89.00 Cr., marking an increase of 10.00 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 22.00% (Mar 2025) to 25.00%, marking an increase of 3.00%.
- For Net Profit, as of Jun 2025, the value is 66.00 Cr.. The value appears strong and on an upward trend. It has increased from 61.00 Cr. (Mar 2025) to 66.00 Cr., marking an increase of 5.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 39.87. The value appears strong and on an upward trend. It has increased from 36.86 (Mar 2025) to 39.87, marking an increase of 3.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:47 am
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020n n 18m | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025n n 16m | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 867 | 940 | 993 | 698 | 849 | 927 | 1,356 | 1,009 | 1,114 | 1,230 | 1,151 | 934 | 1,284 |
| Expenses | 809 | 855 | 877 | 621 | 701 | 723 | 1,037 | 762 | 846 | 905 | 845 | 616 | 869 |
| Operating Profit | 59 | 85 | 116 | 77 | 148 | 204 | 319 | 246 | 268 | 325 | 307 | 319 | 415 |
| OPM % | 7% | 9% | 12% | 11% | 17% | 22% | 24% | 24% | 24% | 26% | 27% | 34% | 32% |
| Other Income | 20 | 22 | 24 | 74 | 768 | 48 | 66 | 18 | 13 | 18 | -5 | 10 | 16 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 |
| Depreciation | 13 | 23 | 25 | 19 | 21 | 17 | 29 | 30 | 27 | 28 | 27 | 17 | 22 |
| Profit before tax | 67 | 83 | 115 | 132 | 895 | 234 | 355 | 233 | 253 | 314 | 273 | 312 | 408 |
| Tax % | 35% | 36% | 31% | 29% | 6% | 32% | 28% | 24% | 24% | 27% | 26% | 25% | |
| Net Profit | 43 | 54 | 79 | 94 | 839 | 159 | 254 | 177 | 193 | 229 | 201 | 234 | 307 |
| EPS in Rs | 26.04 | 32.27 | 47.67 | 56.57 | 505.27 | 95.64 | 153.07 | 106.51 | 115.98 | 138.24 | 121.08 | 141.22 | 184.83 |
| Dividend Payout % | 23% | 23% | 23% | 27% | 87% | 0% | 150% | 122% | 45% | 69% | 215% | 89% |
YoY Net Profit Growth
| Year |
|---|
| YoY Net Profit Growth (%) |
| Change in YoY Net Profit Growth (%) |
No data available for trend analysis.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 0% |
| 3 Years: | -3% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 8% |
| 3 Years: | 10% |
| TTM: | 43% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 6% |
| 3 Years: | 14% |
| 1 Year: | 24% |
| Return on Equity | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 27% |
| 3 Years: | 33% |
| Last Year: | 36% |
Last Updated: September 5, 2025, 12:40 pm
Balance Sheet
Last Updated: December 4, 2025, 1:50 am
| Month | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 538 | 575 | 647 | 717 | 1,524 | 800 | 890 | 687 | 600 | 734 | 522 | 520 | 603 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 3 | 12 | 10 | 8 | 6 |
| Other Liabilities | 154 | 192 | 215 | 258 | 219 | 250 | 269 | 275 | 269 | 338 | 247 | 250 | 268 |
| Total Liabilities | 708 | 784 | 879 | 991 | 1,759 | 1,067 | 1,176 | 986 | 888 | 1,101 | 794 | 794 | 894 |
| Fixed Assets | 110 | 132 | 111 | 115 | 104 | 101 | 101 | 104 | 112 | 144 | 128 | 116 | 106 |
| CWIP | 28 | 7 | 30 | 9 | 17 | 11 | 21 | 39 | 41 | 32 | 6 | 11 | 13 |
| Investments | 24 | 42 | 28 | 70 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 547 | 603 | 711 | 797 | 1,639 | 954 | 1,053 | 843 | 736 | 925 | 660 | 667 | 776 |
| Total Assets | 708 | 784 | 879 | 991 | 1,759 | 1,067 | 1,176 | 986 | 888 | 1,101 | 794 | 794 | 894 |
Below is a detailed analysis of the balance sheet data for Procter & Gamble Health Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 17.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 17.00 Cr..
- For Reserves, as of Sep 2025, the value is 603.00 Cr.. The value appears strong and on an upward trend. It has increased from 520.00 Cr. (Mar 2025) to 603.00 Cr., marking an increase of 83.00 Cr..
- For Borrowings, as of Sep 2025, the value is 6.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 8.00 Cr. (Mar 2025) to 6.00 Cr., marking a decrease of 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 268.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 250.00 Cr. (Mar 2025) to 268.00 Cr., marking an increase of 18.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 894.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 794.00 Cr. (Mar 2025) to 894.00 Cr., marking an increase of 100.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 106.00 Cr.. The value appears to be declining and may need further review. It has decreased from 116.00 Cr. (Mar 2025) to 106.00 Cr., marking a decrease of 10.00 Cr..
- For CWIP, as of Sep 2025, the value is 13.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Mar 2025) to 13.00 Cr., marking an increase of 2.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 776.00 Cr.. The value appears strong and on an upward trend. It has increased from 667.00 Cr. (Mar 2025) to 776.00 Cr., marking an increase of 109.00 Cr..
- For Total Assets, as of Sep 2025, the value is 894.00 Cr.. The value appears strong and on an upward trend. It has increased from 794.00 Cr. (Mar 2025) to 894.00 Cr., marking an increase of 100.00 Cr..
Notably, the Reserves (603.00 Cr.) exceed the Borrowings (6.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020n n 18m | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025n n 16m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 59.00 | 85.00 | 116.00 | 77.00 | 148.00 | 204.00 | 319.00 | 238.00 | 265.00 | 313.00 | 297.00 | 319.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 44 | 49 | 39 | 64 | 28 | 30 | 26 | 22 | 27 | 34 | 27 | 57 |
| Inventory Days | 162 | 140 | 145 | 243 | 154 | 139 | 113 | 138 | 124 | 136 | 120 | 152 |
| Days Payable | 40 | 55 | 67 | 128 | 124 | 106 | 105 | 209 | 185 | 239 | 184 | 239 |
| Cash Conversion Cycle | 166 | 134 | 118 | 179 | 58 | 63 | 34 | -49 | -34 | -69 | -37 | -30 |
| Working Capital Days | 74 | 69 | 52 | 94 | 42 | 22 | 23 | 7 | 17 | 15 | 19 | 48 |
| ROCE % | 12% | 15% | 18% | 16% | 78% | 20% | 29% | 29% | 38% | 45% | 45% | 48% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 692,659 | 0.58 | 396.37 | 596,807 | 2025-12-08 07:42:13 | 16.06% |
| ICICI Prudential Smallcap Fund | 360,975 | 2.44 | 206.57 | 356,022 | 2025-12-14 01:36:52 | 1.39% |
| UTI MNC Fund | 229,559 | 4.57 | 131.37 | 240,895 | 2025-12-14 02:16:25 | -4.71% |
| DSP Healthcare Fund | 159,288 | 2.87 | 91.15 | 158,704 | 2025-12-07 19:34:14 | 0.37% |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 71,471 | 0.63 | 40.9 | N/A | N/A | N/A |
| Aditya Birla Sun Life MNC Fund | 69,716 | 1.1 | 39.9 | N/A | N/A | N/A |
| UTI Healthcare Fund | 67,014 | 3.41 | 38.35 | 35,000 | 2025-12-07 19:34:14 | 91.47% |
| ICICI Prudential Bharat Consumption Fund | 22,442 | 0.39 | 12.84 | N/A | N/A | N/A |
| Aditya Birla Sun Life Pharma & Healthcare Fund | 19,000 | 1.27 | 10.87 | N/A | N/A | N/A |
| HDFC Retirement Savings Fund - Hybrid Equity | 12,000 | 0.39 | 6.87 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 141.00 | 133.00 | 138.00 | 116.00 | 107.00 |
| Diluted EPS (Rs.) | 141.00 | 121.00 | 138.00 | 116.00 | 107.00 |
| Cash EPS (Rs.) | 151.26 | 137.58 | 155.16 | 132.29 | 124.60 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 323.47 | 324.24 | 452.34 | 371.38 | 423.92 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 323.47 | 324.24 | 452.34 | 371.38 | 423.92 |
| Dividend / Share (Rs.) | 125.00 | 260.00 | 95.00 | 52.50 | 130.00 |
| Revenue From Operations / Share (Rs.) | 562.75 | 693.53 | 740.73 | 671.33 | 607.67 |
| PBDIT / Share (Rs.) | 198.04 | 193.75 | 206.67 | 169.20 | 159.11 |
| PBIT / Share (Rs.) | 187.98 | 177.25 | 189.74 | 152.88 | 141.01 |
| PBT / Share (Rs.) | 187.72 | 164.65 | 189.28 | 152.63 | 140.53 |
| Net Profit / Share (Rs.) | 141.21 | 121.07 | 138.23 | 115.97 | 106.51 |
| PBDIT Margin (%) | 35.19 | 27.93 | 27.90 | 25.20 | 26.18 |
| PBIT Margin (%) | 33.40 | 25.55 | 25.61 | 22.77 | 23.20 |
| PBT Margin (%) | 33.35 | 23.74 | 25.55 | 22.73 | 23.12 |
| Net Profit Margin (%) | 25.09 | 17.45 | 18.66 | 17.27 | 17.52 |
| Return on Networth / Equity (%) | 43.65 | 37.34 | 30.55 | 31.22 | 25.12 |
| Return on Capital Employeed (%) | 53.90 | 51.13 | 39.50 | 38.57 | 31.32 |
| Return On Assets (%) | 29.51 | 25.30 | 20.83 | 21.54 | 17.92 |
| Asset Turnover Ratio (%) | 1.18 | 1.21 | 1.23 | 1.19 | 0.93 |
| Current Ratio (X) | 2.44 | 2.39 | 2.62 | 2.60 | 3.04 |
| Quick Ratio (X) | 1.94 | 1.90 | 2.18 | 2.11 | 2.55 |
| Inventory Turnover Ratio (X) | 8.55 | 2.38 | 2.55 | 2.77 | 2.29 |
| Dividend Payout Ratio (NP) (%) | 99.14 | 206.48 | 40.87 | 147.43 | 215.93 |
| Dividend Payout Ratio (CP) (%) | 92.55 | 181.71 | 36.41 | 129.25 | 184.57 |
| Earning Retention Ratio (%) | 0.86 | -106.48 | 59.13 | -47.43 | -115.93 |
| Cash Earning Retention Ratio (%) | 7.45 | -81.71 | 63.59 | -29.25 | -84.57 |
| Interest Coverage Ratio (X) | 764.51 | 446.71 | 445.55 | 668.74 | 330.15 |
| Interest Coverage Ratio (Post Tax) (X) | 546.14 | 308.18 | 299.01 | 459.38 | 222.00 |
| Enterprise Value (Cr.) | 8347.67 | 8138.39 | 8273.45 | 6626.39 | 8817.13 |
| EV / Net Operating Revenue (X) | 8.94 | 7.07 | 6.73 | 5.95 | 8.74 |
| EV / EBITDA (X) | 25.39 | 25.30 | 24.12 | 23.59 | 33.38 |
| MarketCap / Net Operating Revenue (X) | 9.14 | 7.28 | 7.09 | 6.24 | 9.21 |
| Retention Ratios (%) | 0.85 | -106.48 | 59.12 | -47.43 | -115.93 |
| Price / BV (X) | 15.90 | 15.57 | 11.60 | 11.28 | 13.20 |
| Price / Net Operating Revenue (X) | 9.14 | 7.28 | 7.09 | 6.24 | 9.21 |
| EarningsYield | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 |
After reviewing the key financial ratios for Procter & Gamble Health Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 141.00. This value is within the healthy range. It has increased from 133.00 (Mar 24) to 141.00, marking an increase of 8.00.
- For Diluted EPS (Rs.), as of Mar 25, the value is 141.00. This value is within the healthy range. It has increased from 121.00 (Mar 24) to 141.00, marking an increase of 20.00.
- For Cash EPS (Rs.), as of Mar 25, the value is 151.26. This value is within the healthy range. It has increased from 137.58 (Mar 24) to 151.26, marking an increase of 13.68.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 323.47. It has decreased from 324.24 (Mar 24) to 323.47, marking a decrease of 0.77.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 323.47. It has decreased from 324.24 (Mar 24) to 323.47, marking a decrease of 0.77.
- For Dividend / Share (Rs.), as of Mar 25, the value is 125.00. This value exceeds the healthy maximum of 3. It has decreased from 260.00 (Mar 24) to 125.00, marking a decrease of 135.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 562.75. It has decreased from 693.53 (Mar 24) to 562.75, marking a decrease of 130.78.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 198.04. This value is within the healthy range. It has increased from 193.75 (Mar 24) to 198.04, marking an increase of 4.29.
- For PBIT / Share (Rs.), as of Mar 25, the value is 187.98. This value is within the healthy range. It has increased from 177.25 (Mar 24) to 187.98, marking an increase of 10.73.
- For PBT / Share (Rs.), as of Mar 25, the value is 187.72. This value is within the healthy range. It has increased from 164.65 (Mar 24) to 187.72, marking an increase of 23.07.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 141.21. This value is within the healthy range. It has increased from 121.07 (Mar 24) to 141.21, marking an increase of 20.14.
- For PBDIT Margin (%), as of Mar 25, the value is 35.19. This value is within the healthy range. It has increased from 27.93 (Mar 24) to 35.19, marking an increase of 7.26.
- For PBIT Margin (%), as of Mar 25, the value is 33.40. This value exceeds the healthy maximum of 20. It has increased from 25.55 (Mar 24) to 33.40, marking an increase of 7.85.
- For PBT Margin (%), as of Mar 25, the value is 33.35. This value is within the healthy range. It has increased from 23.74 (Mar 24) to 33.35, marking an increase of 9.61.
- For Net Profit Margin (%), as of Mar 25, the value is 25.09. This value exceeds the healthy maximum of 10. It has increased from 17.45 (Mar 24) to 25.09, marking an increase of 7.64.
- For Return on Networth / Equity (%), as of Mar 25, the value is 43.65. This value is within the healthy range. It has increased from 37.34 (Mar 24) to 43.65, marking an increase of 6.31.
- For Return on Capital Employeed (%), as of Mar 25, the value is 53.90. This value is within the healthy range. It has increased from 51.13 (Mar 24) to 53.90, marking an increase of 2.77.
- For Return On Assets (%), as of Mar 25, the value is 29.51. This value is within the healthy range. It has increased from 25.30 (Mar 24) to 29.51, marking an increase of 4.21.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.18. It has decreased from 1.21 (Mar 24) to 1.18, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 2.44. This value is within the healthy range. It has increased from 2.39 (Mar 24) to 2.44, marking an increase of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 1.94. This value is within the healthy range. It has increased from 1.90 (Mar 24) to 1.94, marking an increase of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.55. This value exceeds the healthy maximum of 8. It has increased from 2.38 (Mar 24) to 8.55, marking an increase of 6.17.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 99.14. This value exceeds the healthy maximum of 50. It has decreased from 206.48 (Mar 24) to 99.14, marking a decrease of 107.34.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 92.55. This value exceeds the healthy maximum of 50. It has decreased from 181.71 (Mar 24) to 92.55, marking a decrease of 89.16.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 40. It has increased from -106.48 (Mar 24) to 0.86, marking an increase of 107.34.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 7.45. This value is below the healthy minimum of 40. It has increased from -81.71 (Mar 24) to 7.45, marking an increase of 89.16.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 764.51. This value is within the healthy range. It has increased from 446.71 (Mar 24) to 764.51, marking an increase of 317.80.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 546.14. This value is within the healthy range. It has increased from 308.18 (Mar 24) to 546.14, marking an increase of 237.96.
- For Enterprise Value (Cr.), as of Mar 25, the value is 8,347.67. It has increased from 8,138.39 (Mar 24) to 8,347.67, marking an increase of 209.28.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.94. This value exceeds the healthy maximum of 3. It has increased from 7.07 (Mar 24) to 8.94, marking an increase of 1.87.
- For EV / EBITDA (X), as of Mar 25, the value is 25.39. This value exceeds the healthy maximum of 15. It has increased from 25.30 (Mar 24) to 25.39, marking an increase of 0.09.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 9.14. This value exceeds the healthy maximum of 3. It has increased from 7.28 (Mar 24) to 9.14, marking an increase of 1.86.
- For Retention Ratios (%), as of Mar 25, the value is 0.85. This value is below the healthy minimum of 30. It has increased from -106.48 (Mar 24) to 0.85, marking an increase of 107.33.
- For Price / BV (X), as of Mar 25, the value is 15.90. This value exceeds the healthy maximum of 3. It has increased from 15.57 (Mar 24) to 15.90, marking an increase of 0.33.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 9.14. This value exceeds the healthy maximum of 3. It has increased from 7.28 (Mar 24) to 9.14, marking an increase of 1.86.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Procter & Gamble Health Ltd:
- Net Profit Margin: 25.09%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 53.9% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 43.65% (Industry Average ROE: 14.71%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 546.14
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.94
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 30.8 (Industry average Stock P/E: 42.68)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 25.09%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | P&G Plaza, Cardinal Gracias Road, Mumbai Maharashtra 400009 | investorgrievance.im@pg.com https://www.pghealthindia.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. S Madhavan | Chairman & Ind.Director |
| Mr. Milind Thatte | Managing Director |
| Mr. Lokesh Chandak | Executive Director & CFO |
| Ms. Seema Sambasivan | Non Executive Director |
| Mr. Aalok Agrawal | Non Executive Director |
| Ms. Krishna Sarma | Independent Director |
| Mr. Sharad Tyagi | Independent Director |
FAQ
What is the intrinsic value of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd's intrinsic value (as of 17 December 2025) is 3419.02 which is 39.86% lower the current market price of 5,685.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 9,437 Cr. market cap, FY2025-2026 high/low of 6,739/4,904, reserves of ₹603 Cr, and liabilities of 894 Cr.
What is the Market Cap of Procter & Gamble Health Ltd?
The Market Cap of Procter & Gamble Health Ltd is 9,437 Cr..
What is the current Stock Price of Procter & Gamble Health Ltd as on 17 December 2025?
The current stock price of Procter & Gamble Health Ltd as on 17 December 2025 is 5,685.
What is the High / Low of Procter & Gamble Health Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Procter & Gamble Health Ltd stocks is 6,739/4,904.
What is the Stock P/E of Procter & Gamble Health Ltd?
The Stock P/E of Procter & Gamble Health Ltd is 30.8.
What is the Book Value of Procter & Gamble Health Ltd?
The Book Value of Procter & Gamble Health Ltd is 373.
What is the Dividend Yield of Procter & Gamble Health Ltd?
The Dividend Yield of Procter & Gamble Health Ltd is 2.20 %.
What is the ROCE of Procter & Gamble Health Ltd?
The ROCE of Procter & Gamble Health Ltd is 47.8 %.
What is the ROE of Procter & Gamble Health Ltd?
The ROE of Procter & Gamble Health Ltd is 36.4 %.
What is the Face Value of Procter & Gamble Health Ltd?
The Face Value of Procter & Gamble Health Ltd is 10.0.